Clinical Report: Talking Extractables & Leachables with Smithers Rapra

Background

Extractables and Leachables testing is critical in ensuring the safety and efficacy of pharmaceutical products and medical devices. As regulatory frameworks evolve, the need for robust testing methodologies becomes increasingly important to mitigate risks associated with contaminants.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

• New analytical technologies are enhancing the identification of unknown contaminants.
• The draft ICH Q3E Guideline for E&L testing is undergoing public consultation, indicating a shift towards a risk-based framework.
• ISO 10993-17:2023 provides a toxicological risk assessment framework for interpreting E&L data in biocompatibility evaluations.
• Recent studies have focused on improving inter-laboratory consistency in E&L screening methods.
• Potential adverse effects from leachables include mutagenic and immunogenic risks.

Clinical Implications

Healthcare professionals should stay informed about evolving regulatory guidelines and advancements in E&L testing methodologies to ensure compliance and enhance patient safety. Understanding the implications of leachables on drug products is essential for risk assessment.

Conclusion

The ongoing developments in E&L testing and regulatory frameworks highlight the importance of rigorous testing to safeguard patient health. Continuous advancements in analytical technology will play a vital role in improving testing accuracy and safety outcomes.

Related Resources & Content

1. Smithers Rapra, The Medicine Maker, 2025 -- Talking Extractables & Leachables with Smithers Rapra
2. Glaxo Smith Kline, The Medicine Maker, 2016 -- Talking Extractables & Leachables with Glaxo Smith Kline
3. The Medicine Maker, 2015 -- Testing for leachables in pharmaceutical contact closure materials; a complete ICP-MS, GC-MS & LC-MS workflow
4. The Medicine Maker, 2016 -- Talking Extractables & Leachables testing using Orbitrap based mass spectrometry
5. International Council for Harmonisation of Technical, 2025 -- ICH Q3E Draft Guideline
6. ScienceDirect, 2025 -- Procedural modifications proposed for the screening of substances extracted from pharmaceutical packaging systems
7. the medicine maker — Understanding and Delivering Extractables & Leachables Testing
8. Extractables & Leachables Testing
9. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
10. Procedural modifications proposed for the screening of substances extracted from pharmaceutical packaging systems and medical devices with the goal of improving inter-laboratory consistency of the data generated - ScienceDirect